ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DNL Diurnal Group Plc

27.30
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 27.30 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Diurnal Share Discussion Threads

Showing 4526 to 4550 of 5825 messages
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older
DateSubjectAuthorDiscuss
26/3/2021
12:05
Ching Ching guys Well done all !!!!
s34icknote
26/3/2021
12:04
This is a massive green light for me and my holding will be long term looking for £3 per share or more In the next year
aimmafia
26/3/2021
12:04
Yep let them clear - I would imagine we get ii interest from here
trotterstrading
26/3/2021
12:04
Cannot believe people are selling the news on this. Will be buying more
talk2dubya
26/3/2021
12:04
Agreed. Brokers updates might give a significant leg up.
small crow
26/3/2021
12:03
Profit takers
aimmafia
26/3/2021
12:03
Nice news but someone is dumping into it!
chesty1
26/3/2021
12:02
Slight sell on news I suspect then another go later
aimmafia
26/3/2021
12:01
Very. Nicely done all.
babbler
26/3/2021
12:00
Feels good when your investment convictions come good?
affc21
26/3/2021
11:59
RNS

IDMDNL

RNS Number : 6728T

Diurnal Group PLC

26 March 2021

26 March 2021

Diurnal Group plc

("Diurnal" or the "Company")

European Medicine Agency issues positive opinion for Diurnal's second product in Europe
In preparation for commercial product launch in Europe, Chronocort(R) to be branded as Efmody(R)

Commercial launch anticipated in Q3 2021

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has issued a positive opinion to the European Commission recommending Efmody(R) (hydrocortisone modified-release hard capsules - development name Chronocort(R) ) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). The formal approval of marketing authorisation from the European Commission is anticipated in June 2021, in accordance with the 67-day timeline following the adoption of the positive opinion by the CHMP, together with a decision on grant of Orphan Drug Status.

To facilitate timely commercial availability, Diurnal has already commenced market access activities in its target European territories, with the first commercial launch anticipated in Q3 2021. The Company intends to mirror its strategy for Alkindi(R) (hydrocortisone granules in capsules for opening) by commercialising the product itself in core European markets.

Efmody(R) is a preparation of hydrocortisone that has been specifically designed for patients with CAH, an orphan condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase. Approximately two-thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels. The condition is estimated to affect a total of approximately 41,000 patients in Europe.

Martin Whitaker, Chief Executive Officer of Diurnal, commented:

"We are delighted that the CHMP endorses Efmody(R) as a treatment option for adult and adolescent patients suffering from congenital adrenal hyperplasia. We look forward to expanding our commercial portfolio with the planned launch of Efmody(R) across Europe alongside our first product Alkindi(R) , to provide life-long treatment for patients with congenital adrenal hyperplasia, enabling Diurnal to continue to drive towards becoming a world-leading specialty endocrinology business."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).


For further information, please visit www.diurnal.co.uk or
contact:

+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886
and Sole Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden

+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell

Notes to Editors

About Congenital Adrenal Hyperplasia

dafad
26/3/2021
11:59
To facilitate timely commercial availability, Diurnal has already commenced market access activities in its target European territories, with the first commercial launch anticipated in Q3 2021.
parob
26/3/2021
11:59
Is this boom time?
aimmafia
26/3/2021
11:58
Hopefully you're happy now?Patience, been saying it for months.
mufprat
26/3/2021
11:58
There it is.
small crow
26/3/2021
11:55
I'm expecting £1 to break in the next hour
aimmafia
26/3/2021
11:54
Wider market not even aware of this yet.Looking forward to the RNS!
parob
26/3/2021
11:54
Pretty much nails on P3 US partner and completely derisks the business. IMHO it is now very reasonable to believe DNL will be acquired by a large pharma Co within 2 years for a massive premium
trotterstrading
26/3/2021
11:53
"£3 in 12 months with positive DITEST update" Or TO at £2 long before that?
small crow
26/3/2021
11:53
Yes, I was just wondering when and if to add to my holding.
rafboy
26/3/2021
11:50
The key is,the platform is viable.
geraldus
26/3/2021
11:48
How many other stocks on aim have to regulatory approved drugs...
shrewdmole
26/3/2021
11:48
Depends how long you want to hold Raf by £1.50 minimum short term IMHO. £3 in 12 months with positive DITEST update
trotterstrading
26/3/2021
11:48
Just the start this should trigger a phase 3 partner for US approval and an upfront payment.
shrewdmole
26/3/2021
11:47
Well done all!!!!
trotterstrading
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older

Your Recent History

Delayed Upgrade Clock